Closed Loop Medicine appoints Paul Johnson as Non-Executive Director

Paul will work with the company to drive forward its commercialisation strategy for its portfolio of precision care solutions

Closed Loop Medicine, a TechBio company developing combination prescription drug plus software therapy products that deliver personalised dose optimisation, has appointed Paul Johnson as an Independent Non-Executive Director.

A notable entrepreneur in the industry, Johnson brings unique and extensive experience in the development and scaling of digital healthcare and e-commerce platforms to the Board of Directors. 

Johnson joins at a pivotal stage in the company’s development as it prepares for breakthrough milestones in the progression and commercialisation of its product pipeline.

Johnson is an established leader within the digital healthcare industry, having co-founded Lemonaid Health, one of the first national direct-to-consumer telehealth apps in the US, and led the company as CEO through to its acquisition by consumer genetics and research company, 23andMe, for USD $400 million in 2021.

Johnson then became VP and General Manager, and later COO, of the wider 23andMe consumer business, which includes Lemonaid Health, providing its innovative telemedicine platform to advance 23andMe’s vision of individualised primary care.

Harnessing his specialist experience and expertise in digital platforms and direct-to-consumer medical services, Johnson joins Closed Loop Medicine’s Board to support the leadership team in driving forward the commercialisation strategy for its portfolio of integrated precision care solutions.

Dr Hakim Yadi, CEO and co-founder of Closed Loop Medicine, said: “As we stand on the brink of realising our vast prospects within the industry, Paul's strategic insights and proven track record will be instrumental to steering the company to continued growth and success. His notable achievements and deep expertise in navigating the evolving telemedicine and digital health landscape, particularly through his work at Lemonaid Health and 23andMe, will undoubtedly play a focal role in bolstering the company’s strategic growth and commercialisation of our disruptive platforms.”

You may also like